Wolfe Research raises Leslie’s stock price target on margin gains By Investing.com

Leslie’s reported fiscal Q2 net sales of $184.7 million, up 4.3%, with same-store sales rising 6.6% and gross margin expanding 400 bps to 28.9%. EBITDA came in at negative $30 million, beating consensus by $2 million, while management reaffirmed fiscal 2026 guidance calling for a 5% sales decline at the midpoint and 6% EBITDA growth. Wolfe Research raised its price target to $3 from $2 and maintained an Outperform rating.

Analysis

The important read-through is not the quarter itself but the shape of the turnaround: this is a cost-reset story with operating leverage still far from fully realized. A smaller distribution footprint and store rationalization can keep margins improving even if top-line remains slightly negative, which means the next leg of upside is likely to come from another quarter or two of gross-margin hold plus continued opex discipline rather than demand inflection alone. That makes the stock more sensitive to incremental execution than to absolute sales growth.

The second-order effect is on suppliers and local competitors, not just Leslie’s. As the company trims locations, nearby independents and regional chains may pick up share in displaced trade areas, but they also lose the chance to lean on price-competitive promotional activity from a more rationalized Leslie’s. If management’s pricing investments stick, the category could see a modest deflationary pulse in the near term, pressuring weaker competitors’ gross margins before the volume environment fully normalizes.

The market is likely underestimating how much of the EBITDA bridge is already embedded in the restructuring plan, which cuts both ways. Near-term upside is driven by clean beats and a better guide-through on gross margin, but once the closure and distribution savings are fully recognized, the stock can stall unless comp sales re-accelerate meaningfully. The key risk is that the remaining store base is lower quality than modeled, so a few points of comp deceleration or a weaker summer season could quickly overwhelm the cost savings.

This is a classic months-not-days setup: the next two earnings prints matter more than the current headline. The catalyst path is straightforward — continued margin expansion plus guidance confidence — but the reversal trigger is equally clear: if sales lapse while the company exits the closure program, the market will re-rate it as a shrinking retailer rather than a restructuring winner. Given the current share price, that asymmetry supports tactical upside, but not a broad secular long.

Key Decisions for Investors

• Go long LESL into the next earnings window with a defined stop below recent support; use it as a 2-4 month restructuring trade, not a buy-and-forget core position. Risk/reward is attractive if gross margin holds and EBITDA beats again, but trim aggressively if comps flatten.
• Pair long LESL / short a small-cap discretionary retailer with weaker margin recovery and less balance-sheet optionality. The relative trade isolates execution alpha and reduces market-beta risk if consumer demand softens.
• Consider buying LESL call spreads three to six months out rather than outright stock. The setup is driven by guided EBITDA improvement and cost savings, so convexity is preferable if the market continues to price only liquidation value.
• If LESL rallies sharply on the next print, fade into strength rather than chase above fair-value estimates. The restructuring multiple can compress quickly once investors believe the easy savings are in the numbers.